Kornimate/medical-research-clean huggingface dataset:
home-based tdcs in frontotemporal dementia or alzheimer's disease

Conditions: Mild Cognitive Impairment; Primary Progressive Aphasia; Dementia

Summary: the primary objective of this research is to evaluate the effects of non-invasive brain stimulation and computerized cognitive training on executive functioning in individuals with primary progressive aphasia (ppa), mild cognitive impairment (mci), or dementia. in this study, investigators will use transcranial direct current stimulation (tdcs) to stimulate the left dorsolateral prefrontal cortex (dlpfc). previous studies have demonstrated that tdcs over the dlpfc led to improvements in attention deficit caused by stroke, parkinson's disease, and major depression as well as language deficits caused by neurodegenerative conditions such as primary progressive aphasia or mild cognitive impairment. the investigators seek to expand on this literature by investigating how anodal tdcs paired with and without cognitive training will impact executive functioning in ppa with frontotemporal dementia or alzheimer's disease pathology and mild cognitive impairment/alzheimer's disease (e.g. shifting, updating, monitoring, and manipulation).

in this within-subject cross-over protocol, all participants will receive both, cognitive training and brain stimulation tdcs. participants will be randomly assigned to begin with either cognitive training and brain stimulation (dual therapy) or just brain stimulation (monotherapy) and will receive the complementary therapy program in the second round of treatment. during each period of therapy, participants will receive 50 treatment sessions over the course of approximately 10 weeks. the computerized cognitive training and brain stimulation will both be preprogrammed to be done at home by the participant.

Eligibility criteria:
inclusion criteria: * must be clinically diagnosed with ppa, fronto-temporal dementia (ftd), mci or mild alzheimer's disease (ad). diagnosis will be based on neuropsychological testing, language testing (most commonly the western aphasia battery), mri, and clinical assessment. * must be right-handed. * must be proficient in english. * must have a minimum high-school education. exclusion criteria: * uncorrected visual or hearing impairment by self-report. * stroke/other premorbid neurological disorder affecting the brain. * any other developmental language-based learning disorder other than ppa. * inability to follow directions for baseline tasks. * pre-existing psychiatric disorders such as behavioral disturbances, severe depression, and schizophrenia that do not allow them to comply or follow the study schedule and requirements such as repeated evaluation and therapy will be excluded. exclusion criteria for mri participation: * severe claustrophobia. * cardiac pacemakers or ferromagnetic implants. * pregnant women.
effect of betablocker or aldosterone antagonist therapy on patients with liver cirrhosis

Conditions: Liver Cirrhosis; Portal Hypertension

Summary: the study´s purpose is to investigate the effect of beta blockade or aldosterone antagonist therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients with liver cirrhosis.

cardio-pulmonal complications to patients with liver cirrhosis and portal hypertension determine the patients' prognosis. most patients have hemodynamical changes in circulation with increased cardiac output and decreased systolic function in stress. endothelial dysfunction is a parameter for bad prognosis in cardiovascular disease. the renin-angiotensin-aldosterone-system plays an important role in natrium and volume regulation. descriptions of changes in the peripheral circulation and oxygenation have been deficient up to now. patients with liver cirrhosis and portal hypertension are betablockers and/or aldosterone antagonists routine treatment - effects on peripheral hemodynamics and oxygenation in relation to central hemodynamic changes are deficient.

Eligibility criteria:
inclusion criteria: * liver cirrhosis * clinical indication for treatment with betablocker or aldosterone antagonist * must not have been treated earlier with betablocker or aldosterone antagonist * must have been alcohol abstinent for more than 4 weeks exclusion criteria: * gastrointestinal bleeding in the last 2 weeks * encephalopathy \> grade 1 * acute medical conditions * malignant disease * pregnancy

Keywords: betablocker aldosterone antagonist peripheral haemodynamics cardiac haemodynamics oxygenation
acute kidney injury after cardiac surgery: novel ultrasound techniques for prediction of acute kidney injury

Conditions: Acute Kidney Injury; Acute Renal Failure; Cardiac Surgery

Summary: acute kidney injury (aki) is a frequent and important complication to cardiac surgery. this study will evaluate the diagnostic ability of ultrasonographic measures of blood flow in kidneys and liver in predicting aki after cardiac surgery.

acute kidney injury (aki) is a frequent and important complication to cardiac surgery. the pathophysiology is multifactorial, but renal functions in this setting is determined by a complex interplay between renal perfusion, fluid status, cardiac output, mean arterial pressure and back pressure to venous outflow. renal perfusion may be quantified with novel ultrasound techniques. ultrasonography of the kidney and renal vasculature allows for assessment of renal afferent flow and renal venous flow and, together with venous flow patterns of the portal vein and liver veins, may identify patients in risk of aki. the study is observational and will describe the diagnostic accuracy of the ultrasound measures in predicting postoperative aki. patients will be examined with ultrasound of kidney and liver flow along with echocardiography on on the day before surgery and on the 1st and 4th. in addition, patients are followed with markers of kidney function, fluid balance and invasive measures of mean arterial pressure and central venous pressure.

Eligibility criteria:
inclusion criteria: * all patients ≥ 18 years * scheduled for on-pump cardiac surgery * oral and written consent and * 1 of the following risk factors for development of postoperative aki may be included: * age \> 70 years; * nyha (new york heart association) 3+4; * insulin dependent diabetes; * glomerular filtration rate \< 60 ml/min/1,73 m2; * ejection fraction \< 35; * surgery: * combined cabg and valve surgery; * any valve surgery except isolated aortic-valve surgery; * redo surgery; * endocarditis; * peripheral vascular disease. exclusion criteria: * insufficient ultrasonographic imaging of the kidneys; * known morphological kidney disease; * preoperative dialysis; * prior participation in the study.

Keywords: ultrasound ultrasonographic flow measures fluid treatment
evaluation of end of life quality of care

Conditions: Neoplasm Malignant; Quality of Life; End of Life Care

Summary: the study uses a mixed method study to evaluate wether the use of the indicators of the quality of end-of-life cancer care, developed by earle et al \[earle jco 2003; doi: 10.1200/jco.2003.03.059\] would be relevant and measurable in france. the qualitative part of study was designed to investigate the representations of quality by face-to face interviews with family carer of recently deceased cancer patients, and with their oncologists, and nurses. the quantitative part of the study, consisted in a decedents case series analysis, diagnosed with advanced cancer and followed up in 5 centers. data on trajectory of care were collected from different complementary sources associating national mortality data, hospital activity data, and health records. the study was approved by the french data protection authority (cnil) number 611273.


Eligibility criteria:
inclusion criteria * patients aged ≥ 18, * diagnosed with advanced cancer (recruited from hospital activity data, by a stay with a icd code of metastatic cancer between oct 1st, 2009 and dec 31, 2010) * deceased between, jan 1st, 2010 and dec 31, 2010 (vital status identified either from hospital activity data, or from national mortality statistics) exclusion criteria: * diagnosis with non solid tumor (haematology) * age \< 18
exploratory study on safety of peek knee prosthesis

Conditions: Rheumatoid Arthritis of Knee; Osteoarthritis of the Knee

Summary: in this study, 10 subjects will be underwent total knee arthroplasty with peek knee prosthesis and be followed up 3, 6, and 12 months after surgery. the safety of the knee prosthesis for total knee arthroplasty will be investigated based on x-ray, magnetic resonance imaging, thin-section ct, hematological indexes, knee function, complications and the occurrence of serious adverse events at the 12-month follow-up.

according to the involved person's biomedical research ethics review method "(national health and family planning commission (11)) and the medical and health institutions to carry out the researchers launched a clinical research management method" (draft) on request, for national key development plan required for research and development production of peek knee prosthesis for clinical trials. in this study, 10 subjects will be underwent total knee arthroplasty with peek knee prosthesis and be followed up 3, 6, and 12 months after surgery. the safety of the knee prosthesis for total knee arthroplasty will be investigated based on x-ray, magnetic resonance imaging, thin-section ct, hematological indexes, knee function, complications and the occurrence of serious adverse events at the 12-month follow-up. since this study is an exploratory study, all subjects will be retrospectively studied one year after the end of the study.

Eligibility criteria:
inclusion criteria: * male and female subjects aged 55 years of age or older and less than 74 years of age, younger subjects should have urgent need for surgery. * subjects skeletal maturity. * subjects appropriate for total knee replacement, such as noninflammatory degenerative joint diseases (such as osteoarthritis, traumatic arthritis, or ischemic necrosis); inflammatory degenerative joint diseases (including rheumatoid arthritis); correction of functional deformity. * the diseased side knee appropriate for primary total knee arthroplasty . * subjects or guardian is willing and able to sign the informed consent form . exclusion criteria: * subjects with knee instability or abnormal gait caused by neuromuscular insufficiency. * subjects with bilateral knee joint disease who are expected to require replacement of both knees during the course of the study (i.e., within the next 12 months) . * alcoholics, drug addicts and drug abusers. * subjects with severe diabetes (fasting blood glucose \> 10mmol/l) * body mass index, bmi\>35. * female subjects who are pregnant or lactating. * subjects have disease limited their participation in the investigation or have an existing condition that would compromise their participation and follow-up in this clinical investigation. * in the month before inclusion, subjects who participated in clinical studies of other drugs, biological agents or medical devices and failed to meet the main research endpoints. * other conditions, in the opinion of the investigator, are inappropriate for participation in this clinical investigation.

Keywords: tka peek knee prosthesis
requirement of propofol for induction of unconsciousness in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is the second most prevalent neurodegenerative disease. the investigators clinical experience showed a trend of delayed emergence among patients undergoing deep brain stimulator (dbs) implantation and pulse generator placement under general anesthesia. abnormal pharmacodynamics might be present among these patients, which had never been investigated.


Eligibility criteria:
inclusion criteria: * patients with parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement under general anesthesia * non-parkinsonian patients without parkinson's disease undergoing intracranial surgery under general anesthesia exclusion criteria: * asa score higher than class iii * predicted difficult airway * hearing impairment * inability to corporate with instruction * alcohol or drug abuser * patients refusing to provide informed consent

Keywords: parkinson's disease propofol deep brain stimulator
the effect of information on physical fitness measures and training in overweight children

Conditions: Childhood Obesity

Summary: in the present study the investigators will examine the impact of varying information (positive compared to standard information) concerning a drink for improving physical fitness in overweight children.

the present study will explore the short and medium term effects of receiving information concerning a drink (water) (positive compared to standard information) on the physical fitness in overweight children. study subjects will be 30 overweight children aged 6 to 13, new participates in a nutritional, behavioral sport program,the control group of 30 normal weight children. the first stage of the study the investigators will examine the short-term influence of different types of information concerning water on subjects' fitness which will be measured by treadmill performance. first, the water will be presented to the participants children as an ordinary water while in the second case it will be presented as an "energy drink". the second stage of the study will examine the impact of varying information on the subjects' sports participation/level of physical activity over a 6 week period of training, study subjects will be 30 over-weight children aged 6 to 13, who participate in a nutritional, behavioral sport program. during this period, information on the type of drink will be changed every week. children will be assessed in all training sessions and their level of activity will be monitored to examine whether the information on the drink led to a different exercise behavior. the study hypothesis is that the use of these positive information will increase participants' fitness and levels of activity compared to standard information.

Eligibility criteria:
inclusion criteria: * pre pubertal children * study group: bmi precentiles over 85 (overweight and obese children) * control group: bmi precentiles between 5-85 (normal weight children) exclusion criteria: * children with organic disease * competitive athlete

Keywords: physical fitness exercise childhood obesity information
therapeutic equivalence study of generic brinzolamide vs azopt

Conditions: Glaucoma; Open Angle or Ocular Hypertension

Summary: the main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with azopttm (brinzolamide ophthalmic suspension 1%) dosed three times daily in iop reduction in patients with poag or oh.


Eligibility criteria:
inclusion criteria: * male and females 18 years of age or older, * diagnosed with primary open-angle glaucoma or ocular hypertension. exclusion criteria: * patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma, * ocular hypertension.
a study for participants with major depression

Conditions: Major Depressive Disorder

Summary: this is a study to assess the safety and effectiveness of ly2216684 compared to placebo in treating adults with major depressive disorder.


Eligibility criteria:
inclusion criteria: * meet criteria for major depressive disorder (mdd) without psychotic features. * have education level and a degree of understanding such that the participant can communicate with the site study personnel. * judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures, including venipuncture, and examinations required by the protocol. exclusion criteria: * have had any additional, ongoing psychiatric condition other than major depression or dysthymia that was considered the primary diagnosis within 6 months of the first study visit. * have a lifetime history of bipolar i or ii disorder, psychotic disorder, or a factitious disorder. * are judged to be at high risk for imminently harming themselves or others. * have a serious medical illness, including any cardiovascular, hepatic, respiratory, hematologic, endocrinologic, neurologic disease, or clinically significant laboratory or electrocardiogram (ecg) abnormality. clinically significant lab abnormalities are those which, in the judgment of the investigator, indicate a serious medical problem or require intervention. * have any diagnosed medical condition which could be exacerbated by treatment with ly2216684, including hypertension, increased heart rate, arrhythmias, heart disease, narrow angle glaucoma, or urinary hesitancy.
clinical and therapeutic characteristics of geriatric patients hospitalized for heart failure (aging hf study (age and heart failure in geriatrics))

Conditions: Patients Hospitalized in Geriatrics for Heart Failure; Patients Aged 75 and Over

Summary: this retrospective (between april 2020 and december 2023) then prospective (between january 2024 and august 2026), non-interventional cohort study has as its main objective to evaluate the clinical and therapeutic characteristics of patients aged 75 and over hospitalized in geriatrics for heart failure and also to evaluate the clinical characteristics and triggering factor(s) of acute heart failure.

multicenter study, including patients aged 75 and over, hospitalized in geriatrics and having suffered heart failure in the geriatric wards of 3 centers. the following elements will be collected: * demographic data * history (comorbidities) * type of heart disease * frailty criteria * clinical signs of heart failure * geriatric syndromes (falls, cognitive disorders, (mmse) confusion, malnutrition, loss of autonomy (adl, iadl), bedsores) * biology available (cbc, ionogram, creatinine, nt pro bnp, bhc, troponin, tsh, hba1c) * ecg and echocardiography data * treatment on admission, during stay and on discharge * mode of discharge and length of stay * follow-up at 3, 6, 9 months and one year, through telephone calls with the patient, caregiver or attending physician. questions will cover various aspects of health and quality of life, physical activity limitations, autonomy, symptoms, anxiety, depression, as well as neurocognitive status (using adapted questions).

Eligibility criteria:
inclusion criteria: * patients aged 75 and over hospitalized in a geriatric ward with heart failure no oral opposition from patient exclusion criteria: * patient under 75 years of age patient not wishing to participate in the study subject under guardianship/curatorship/supervision of justice

Keywords: heart failure geriatrics age
triamcinolone acetonide as an adjuvant to pre-emptive scalp infiltration for relief of post-craniotomy pain in adults

Conditions: Pain, Postoperative

Summary: pain is common for the first 2 days after major craniotomy. a majority of patients would suffer from moderate-to-severe postoperative pain after undergoing craniotomy. inadequate analgesia induced sympathetically mediated hypertension may lead to an increased risk for post-operative complications. adequate pain control is essential for patients' prognosis and their postoperative life quality. pain after craniotomy derives from the scalp and pericranial muscles. local anesthetics administered around the incision have been performed clinically. however, some studies revealed that the analgesic effect of local anesthetics was not unsatisfactory due to its short pain relief duration. pain is common for the first 2 days after major elective intracranial surgery, and the relatively short analgesic time of scalp infiltration does not seem to meet the requirements of craniotomy. steroid such as triamcinolone acetonide as an adjuvant to local anesthetics intra-articular injected locally ameliorated pain intensity inarthroscopic knee surgery or total knee arthroplasty. however, there has not been reported about local application of triamcinolone acetonide on scalp infiltration. thus, the investigators suppose that pre-emptive scalp infiltration with steroid (triamcinolone acetonide) plus local anesthetic (ropivacaine) could relieve postoperative pain after craniotomy in adults.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective craniotomy for resection of tumour under general anaesthesia; * american society of anesthesiologists (asa) physical status of i ,ii or iii; * participates with an anticipated fully recovery within 2 hours postoperatively; exclusion criteria: * history of craniotomy; * expected delayed extubation or no plan to extubate; * participants who cannot use a patient-controlled analgesia (pca) device; * participants who cannot understand the instructions of a numeral rating scale (nrs) 35 before surgery; * extreme body mass index (bmi) (\ 35); * allergy to opioids, triamcinolone acetonide or ropivacaine; * history of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects; * history of psychiatric disorders, uncontrolled epilepsy or chronic headache; * pregnant or at breastfeeding; * symptomatic cardiopulmonary, renal, or liver dysfunction or history of diabetes; * preoperative glasgow coma scale\< 15; * suspicion of intracranial hypertension; * peri-incisional infection; * participants who have received radiation therapy and chemotherapy preoperatively or with a high probability to require a postoperative radiation therapy and chemotherapy according to the preoperative imaging.

Keywords: postoperative pain; post-craniotomy pre-emptive scalp infiltration ropivacaine triamcinolone acetonide
anlotinib therapy in patients with advanced lung cancer.

Conditions: Lung Neoplasms

Summary: purpose of the study: to observe the efficacy and safety of anlotinib hydrochloric therapy in patients with advanced lung cancer in real world. subjects of the study: advanced lung cancer. methods of the study: this is a real world, prospective, non-interventional, follow-up registration study. patients will get anlotinib according to their condition and willingness. anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. after the procedure, regular follow up after every cycle. end point: primary end point: progression-free survival (pfs). secondary end points: overall survival (os), disease control rate (dcr), overall response rate (orr).


Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age, man or woman, who had to provide written informed consent prior to enrollment. 2. patients who had to have histologically and/or cytologically confirmed nsclc that failed at least 2 kinds of systemic chemotherapy (third line or beyond), or who will obtain benefit from antiangiogenic therapy after investigator's assessment. 3. eastern cooperative oncology group performance status of 0-2. exclusion criteria: 1. contraindication of anlotinib. 2. pregnant or lactating women. 3. other patients who can't enroll after investigator's assessment.